All In Biotech

Investigational drug · Phase 3

Camlipixant

Also called: BLU-5937

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Refractory Chronic Cough, Cough, Irritable Bowel Syndrome.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

3 still active

All registered trials

9

Any phase or sponsor naming "Camlipixant"

First trial start

2022

Oct 25, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Camlipixant", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Refractory Chronic Cough
  • Cough
  • Irritable Bowel Syndrome

Approved drugs for the same conditions: Irritable bowel syndrome · Rare and genetic disease · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Camlipixant" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 18 on PubMed

Also in development for Refractory Chronic Cough

  • HW091077Phase 21 trial

    Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Refractory Chronic Cough

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.